Roche's Oncology and Personalized Medicine Expertise Support a Wide Moat
We may revisit our near-term estimates following Roche's strong top-line results in the first quarter, but we do not anticipate a material change to our CHF 333/$42 fair value estimate for wide-moat Roche. We continue to believe that the market underappreciates the firm's pipeline and new marketed drugs, and we think the firm's wide moat protects cash flows despite strong headwinds from biosimilar versions of Herceptin, Rituxan, and Avastin (which together represented 36% of 2018 sales). Roche s...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.